Video

Dr. Piotrowska on the Management of Paronychia Associated With EGFR TKIs

Zofia Piotrowska, MD, discusses the management of paronychia associated with EGFR TKIs.

Zofia Piotrowska, MD, assistant professor of medicine, Harvard Medical School, assistant in medicine, Massachusetts General Hospital, discusses the management of paronychia associated with EGFR TKIs.

Although paronychia is an adverse effect (AE) commonly associated with all the class of EGFR TKIs, many patients do not recognize this as a treatment-related AE, Piotrowska says. Patients who experience paronychia may turn to a podiatrist or primary care physician, and an oncologist may be unaware of the AE as a result, Piotrowska explains. Educating patients about the possibility of paronychia as an AE associated with an EGFR TKI is important, she stresses.

When patients present with mild symptoms of paronychia, soaking nails with warm water and Epsom salt or topical steroids can be helpful, Piotrowska continues. If symptoms are ongoing and not improving, dose interruptions may be useful in the event of severe cases of paronychia, she adds. For patients with ongoing and recurrent paronychia, a referral to a dermatologist can also help them manage the AE, Piotrowska concludes.

Sponsored by Takeda Oncology

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD